If you have PCOS, you’ve probably been told the same things. Lose weight. Exercise more. Take the pill. Maybe try metformin.
What you probably haven’t been told about is inositol.
That’s a significant omission. Because the evidence for inositol in PCOS management is not preliminary or speculative. It’s substantial, specific, and growing steadily — with multiple randomised controlled trials, meta-analyses, and clinical guidelines in Europe already incorporating it into recommended care.
Women with PCOS deserve to know this option exists.
PCOS Is Fundamentally an Insulin Problem
Understanding why inositol works starts with understanding what PCOS actually is at a biological level.
Polycystic ovary syndrome affects roughly 1 in 10 women of reproductive age. Its hallmarks — irregular periods, elevated androgens, multiple ovarian cysts visible on ultrasound — are well known. What’s less well communicated is that insulin resistance sits at the root of most cases.
Up to 70% of women with PCOS have some degree of insulin resistance, regardless of body weight. Insulin resistance means cells respond poorly to insulin signalling. The pancreas compensates by producing more insulin. Elevated insulin then stimulates the ovaries to produce excess testosterone. Excess testosterone disrupts ovulation. Disrupted ovulation drives irregular cycles, elevated LH, and the hormonal imbalances that define the condition.
Fix the insulin problem. Improve the hormonal picture. That’s the logic — and it’s where inositol enters.
What Inositol Actually Is
Inositol is a naturally occurring sugar alcohol found in foods including fruits, beans, grains, and nuts. The body produces it endogenously — primarily in the kidneys — and it acts as a secondary messenger in insulin signalling pathways.
There are nine forms of inositol. Two matter most for PCOS: myo-inositol (MI) and D-chiro-inositol (DCI).
Myo-inositol is the primary form involved in insulin signal transduction. It helps cells respond to insulin more effectively, reducing the insulin resistance that drives the hormonal cascade in PCOS.
D-chiro-inositol is involved downstream in glucose metabolism and the regulation of androgen synthesis in the ovaries.
In healthy tissue, the body converts myo-inositol to D-chiro-inositol at a ratio calibrated to the specific needs of each tissue type. Research has found that women with PCOS have disrupted inositol metabolism — their tissues don’t convert efficiently, producing functional inositol deficiency even when overall intake is adequate. Supplementation restores this balance directly.
What the Clinical Trials Show
The inositol PCOS evidence base is genuinely impressive.
A landmark 2007 study published in the New England Journal of Medicine — one of the most rigorous medical journals in the world — found that myo-inositol supplementation in women with PCOS significantly improved ovulation frequency, reduced testosterone levels, lowered fasting insulin, and improved lipid profiles compared to placebo. Forty-six percent of women in the myo-inositol group ovulated during the study period, compared to 18% in the placebo group.
Subsequent trials confirmed and extended these findings. A 2019 meta-analysis published in Reproductive BioMedicine Online analysed fifteen clinical trials and concluded that myo-inositol supplementation consistently improved hormonal parameters — including reduced LH, reduced testosterone, improved FSH/LH ratio — alongside insulin sensitivity in women with PCOS.
The combination of myo-inositol and D-chiro-inositol has received particular attention. A ratio of 40:1 — mirroring the naturally occurring ratio in healthy human plasma — appears to deliver superior outcomes compared to either form alone. Multiple trials using this ratio show improvements in ovulation, cycle regularity, androgen levels, and metabolic markers.
Inositol vs. Metformin
Metformin is the most commonly prescribed medication for PCOS-related insulin resistance. It works. But it causes significant gastrointestinal side effects — nausea, diarrhoea, stomach cramps — that lead many women to reduce doses or stop taking it.
Head-to-head trials comparing myo-inositol to metformin show comparable efficacy on insulin sensitivity, androgen levels, and ovulation restoration — with inositol producing significantly fewer side effects.
A 2017 systematic review in Gynecological Endocrinology concluded that myo-inositol represents a valid alternative to metformin for improving insulin sensitivity and hormonal balance in PCOS, with a superior tolerability profile.
Inositol is not a prescription drug. It has no significant side effect profile at standard doses. It requires no monitoring. For women who cannot tolerate metformin or prefer a nutritional approach, that comparison matters enormously.
What Inositol Won’t Do
Honesty here matters.
Inositol addresses the insulin resistance and hormonal dysregulation driving PCOS. It doesn’t cure the condition. Women with PCOS whose primary driver is something other than insulin resistance — a smaller subset — may see less pronounced benefit.
Results take time. Most trials run for three to six months before assessing outcomes. Ovarian cycles and hormonal patterns don’t reset overnight. Consistent daily supplementation over several months is what the evidence supports — not short-term testing.
Practical Guidance
Standard clinical doses from the trial literature sit at 2–4 grams of myo-inositol daily, often taken in two divided doses. Products combining myo-inositol and D-chiro-inositol at a 40:1 ratio are supported by the strongest emerging evidence.
Inositol is well tolerated. Mild nausea at the start is the most commonly reported side effect, typically resolving within the first week. Taking it with food reduces this further.
Women trying to conceive should inform their fertility specialist or GP before starting, as inositol can restore ovulation — which is the intended effect, but worth monitoring clinically.
The Bottom Line
Inositol PCOS research has reached a point where dismissing it as an unproven supplement claim is no longer accurate. The evidence base is large, consistent, and specific. European fertility guidelines already acknowledge its role. Women living with PCOS deserve access to this information — not as a replacement for medical care, but as a well-evidenced option within it.